Pioneering Targeted Drug Development Strategies

TorMagnus is building the future of drug development by combining scientific and computational principles through machine learning.

Better Targets

Better Therapies

Better Targets

Better Therapies

Better Targets

Better Therapies

Better Targets

Better Therapies

Where We Are Now

Parkinson's Disease

Our immediate efforts are focused on the identification of converging pathways and therapeutic targets for Parkinson's disease. Parkinson's disease is the second most common neurodegenerative disease in the U.S. and is expected to afflict over 1 million U.S. patients in the next decade.
Scroll Down

Where We Are Headed

Multi-Disease Deployment

We strive to facilitate the development of targeted therapies for patients with different forms of Parkinsons's disease. Our pipeline is highly scalable, with the potential for numerous future applications to other neurodegenerative diseases and therapeutic areas.

Our Approach

We leverage genetics and computation to identify novel drug targets.
Artificial Intelligence

Machine Learning

Our algorithms identify converging disease pathways and therapeutic targets.
Rack of lab test tubes

Target Validation

We validate our computationally-identified targets' involvement in disease in the lab.

Small Molecule Development

We develop small molecule modulators against our top validated targets.

Subscribe to Our Newsletter!

More updates coming soon.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.